Stay updated with breaking news from Sinomab Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...
Panellists say Hong Kong excels in biotech research, but needs to attract more talent and reassess its regulatory strategy Prenetics shows the future of healthcare is intertwined with that of biotech, as they display their new at-home rapid detection system for infectious diseases
Collaboration consolidates Everest's leadership in the renal space Everest Medicines will pay Sinovent and SinoMab USD $12 million in upfront and up to $549 million in total development, regulatory, and commercial milestone payments SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals...
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent...